Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of AMG 529 in Healthy Subjects
NCT03170193Phase 1Completed
- Sponsor
- Amgen
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypercholesterolemia comparing AMG 529 with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events (AEs) up to 57 days. Started May 2017; status: completed.
02
Drugs
AMG 529
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03170193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170193.